Carasent AB (publ) is a Swedish company founded in 1997 and headquartered in Gothenburg, specializing in digital healthcare solutions, primarily focusing on electronic health record (EHR) systems. Carasent develops cloud-based EHR systems and platform services aimed at improving healthcare workflows and operational efficiency. The company's notable products include Webdoc, which is used by over 800 healthcare providers in the Nordic region, as well as Metodika, Ad Curis, Ad Opus, and Data-AL, all of which are EHR systems. Additionally, the company offers Medrave, a decision support system, and HPI Plustoo, an occupational health platform. Operating on a subscription-based model, Carasent provides its solutions to healthcare providers across the Nordic countries and Germany, serving the healthcare, rehabilitation, and occupational health sectors. As of August 15, 2026, Carasent has a market capitalization of approximately $183.76 million USD and is listed on Nasdaq Stockholm under the ticker symbol CARA. The company employs around 236 individuals and has offices in Gothenburg, Stockholm, Oslo, Dale, and Neu-Ulm. In 2024, Carasent underwent a merger that led to a share listing on Nasdaq Stockholm, and it achieved ISO 14001 certification, indicating its commitment to sustainability. The current CEO is Daniel Öhman.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
Carasent AB (publ)'s offering is currently approved on OTHER. Carasent AB (publ) is headquartered in Sweden. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Carasent AB (publ).
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/carasent-ab-publ" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Carasent AB (publ) — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/carasent-ab-publ?theme=light as the src instead.
https://www.discoveripo.com/ipo/carasent-ab-publ/opengraph-image
Carasent AB (publ) IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/carasent-ab-publ?utm_source=embed&utm_medium=text&utm_campaign=carasent-ab-publ
Get emailed when Carasent AB (publ)'s terms, price, or expected date change — no weekly noise, just this company.
Carasent AB (publ) is listing on OTHER.
Carasent AB (publ) is a Swedish company founded in 1997 and headquartered in Gothenburg, specializing in digital healthcare solutions, primarily focusing on electronic health record (EHR) systems. Carasent develops cloud-based EHR systems and platform services aimed at improving healthcare workflows and operational efficiency. The company's notable products include Webdoc, which is used by over 800 healthcare providers in the Nordic region, as well as Metodika, Ad Curis, Ad Opus, and Data-AL, all of which are EHR systems. Additionally, the company offers Medrave, a decision support system, and HPI Plustoo, an occupational health platform. Operating on a subscription-based model, Carasent provides its solutions to healthcare providers across the Nordic countries and Germany, serving the healthcare, rehabilitation, and occupational health sectors. As of August 15, 2026, Carasent has a market capitalization of approximately $183.76 million USD and is listed on Nasdaq Stockholm under the ticker symbol CARA. The company employs around 236 individuals and has offices in Gothenburg, Stockholm, Oslo, Dale, and Neu-Ulm. In 2024, Carasent underwent a merger that led to a share listing on Nasdaq Stockholm, and it achieved ISO 14001 certification, indicating its commitment to sustainability. The current CEO is Daniel Öhman.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy